Genetic Technologies Appoints Chief Executive Officer and

Genetic Technologies Appoints Chief Executive Officer and
Non-Executive Director 
MELBOURNE, AUSTRALIA -- (Marketwire) -- 12/10/12 --  Genetic
Technologies Limited (ASX: GTG) (NASDAQ: GENE) announced today the
appointments of Ms. Alison Mew to the position of Chief Executive
Officer and Mr. Ben Silluzio as a Non-Executive Director.  
"The Board is extremely pleased that Ms. Mew has accepted the
Company's offer to become Chief Executive Officer. In her previous
role as Chief Operating Officer, a position she held for more than
three years, Alison played a key role in the establishment of the
Company's U.S. operations along with securing the Australian
laboratory's U.S. compliance. We are confident that Alison is well
placed to lead the Company through its next stages of development,"
commented Dr. Mal Brandon, Chairman of Genetic Technologies. 
Mr. Silluzio specialises in the provision of advice for sophisticated
investors, institutional clients and high net worth families in
Melbourne, nationally and abroad. Currently, he serves as the
managing partner and desk head of RBS Morgans Family Office, and is
also a director of Private Branded Beverages Ltd., a public unlisted
company, and is a former President and Chairman of the Italian
Chamber of Commerce. Previously, Mr. Silluzio has held several senior
positions in the stockbroking and funds management industries,
including: Director of UBS Wealth Management Australia, Senior Vice
President of Credit Suisse First Boston in Melbourne, Vice President
and member of the "Smith Barney Century Council" at Citigroup Smith
Barney in Melbourne and as an institutional client advisor at
Colonial Institutional Stockbroking in Sydney and Melbourne. 
Dr. Mal Brandon added, "The Board is also pleased to welcome Mr.
Silluzio. We are confident that he will bring valuable skills,
contacts and experience which will assist the Company to expand its
profile with the wider investment community." 
About BREVAGen(TM)
 The BREVAGen(TM) breast cancer risk
stratification test is a novel genetic test panel that examines a
patient's DNA to detect the absence or presence of certain common
genetic variations (SNPs) associated with an increased risk for
developing breast cancer. The test is designed to help physicians
assess aggregate breast cancer risk from these genetic markers, plus
factors from a standard clinical assessment based on a patient's
family and personal history, thus giving a clearer picture of an
individual woman's risk of developing breast cancer. The BREVAGen(TM)
test may be especially useful for women predisposed to hormone
dependant breast cancer, including those who have undergone breast
biopsies, as the test will provide information that can help
physicians recommend alternative courses of action, such as more
vigilant, targeted surveillance or preventive therapy, on a
personalized patient-by-patient basis. For more information, please
visit http://www.brevagen.com, or http://www.brevagen.com.au  
About Genetic Technologies Limited
 Genetic Technologies is an
established diagnostics company with more than 20 years of experience
in commercializing genetic testing, non-coding DNA and product
patenting. The Company has operations in Australia and the U.S. and
is dual-listed on the ASX (GTG.AX) and NASDAQ (GENE). Genetic
Technologies is focused on the commercialization of its patent
portfolio through an active out-licensing program and the global
expansion of its oncology and cancer management diagnostics assets.
Its U.S. subsidiary, Phenogen Sciences, offers novel predictive
testing and assessment tools to help physicians proactively manage
women's health. Phenogen's lead product, BREVAGen(TM), is a first in
class, clinically validated risk assessment test for non-familial
breast cancer. For more information, please visit
http://www.gtglabs.com, http://www.phenogensciences.com. 
Safe Harbor Statement
 Any statements in this press release that
relate to the Company's expectations are forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act.
The Private Securities Litigation Reform Act of 1995 (PSLRA)
implemented several significant substantive changes affecting certain
cases brought under the federal securities laws, including changes
related to pleading, discovery, liability, class representation and
awards fees. Since this information may involve risks and
uncertainties and are subject to change at any time, the Company's
actual results may differ materially from expected results.
Additional risks associated with Genetic Technologies' business can
be found in its periodic filings with the SEC. 
FOR FURTHER INFORMATION PLEASE CONTACT
Dr. Mal Brandon 
Chairman 
Genetic Technologies Limited 
Phone: +61 3 8412 7000 
Laura Landry (USA)
Blueprint Life Science Group
+1 (415) 375.3340 Ext. 103 
 
 
Press spacebar to pause and continue. Press esc to stop.